Literature DB >> 17686378

Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Thor Tejada1, Alessia Fornoni, Oliver Lenz, Barry J Materson.   

Abstract

Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker. It is even more effective when used in combination with other antihypertensive medications, including hydrochlorothiazide. When antihypertensive calcium channel blockers were first introduced, evidence in the laboratory that they had some natriuretic properties was adduced to suggest that they would be "the diuretics of the 1990s." This turned out not to be the case. Because of its clinical efficacy, amlodipine is frequently used in fixed-dose combination products, but it is not likely to replace hydrochlorothiazide.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686378     DOI: 10.1007/s11906-007-0052-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  53 in total

1.  Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.

Authors:  Kenneth A Jamerson; Oliseyenum Nwose; Lisa Jean-Louis; Lesley Schofield; Das Purkayastha; Michelle Baron
Journal:  Am J Hypertens       Date:  2004-06       Impact factor: 2.689

2.  Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.

Authors:  Victor Aboyans; Philippe Lacroix; Claude Cassat
Journal:  JAMA       Date:  2005-03-09       Impact factor: 56.272

3.  A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.

Authors:  J Doyle; P Omvik; S Arikian; J Casciano; R Casciano; M A Gonzalez; R Arocho
Journal:  Manag Care Interface       Date:  2001-03

4.  Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation.

Authors:  D E Hilleman; K L Ryschon; S M Mohiuddin; R L Wurdeman
Journal:  J Hum Hypertens       Date:  1999-07       Impact factor: 3.012

5.  Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials.

Authors:  Ji-Guang Wang; Jan A Staessen; Yan Li; Luc M Van Bortel; Tim Nawrot; Robert Fagard; Franz H Messerli; Michel Safar
Journal:  Stroke       Date:  2006-06-08       Impact factor: 7.914

6.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks.

Authors:  W D Hall; J W Reed; J M Flack; C Yunis; J Preisser
Journal:  Arch Intern Med       Date:  1998-10-12

10.  Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.

Authors:  K Homma; K Hayashi; T Kanda; K Yoshioka; I Takamatsu; S Tatematsu; H Kumagai; S Wakino; T Saruta
Journal:  J Hum Hypertens       Date:  2004-12       Impact factor: 3.012

View more
  2 in total

1.  Comparative effectiveness analysis of amlodipine/renin-angiotensin system blocker combinations.

Authors:  C Venkata S Ram; Joseph Vasey; Sumeet Panjabi; Chunlin Qian; Ruth Quah
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-13       Impact factor: 3.738

Review 2.  Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.

Authors:  Jasmina Varagic; Henry Punzi; Carlos M Ferrario
Journal:  Integr Blood Press Control       Date:  2014-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.